Inside view

摘要

Identifying new medical treatments has become increasingly difficult in recent years. With myriad generic drugs available and intense pressure on healthcare budgets, those seeking to discover better medicines for patients must take a more innovative approach. Since Tetsuyuki Maruyama took up his role as head of research at Japan's largest pharmaceutical company in 2010, he has overhauled its process of identifying promising treatments. Here he explains how greater diversity and innovation helps Takeda's research division become a truly global organisation.